Thrombus Distribution in Vaccine-induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Article Hematology

Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources

Andreas Greinacher et al.

Summary: VITT is a rare but severe immunological reaction to non-replicable adenoviral vector-based COVID-19 vaccines, causing extreme activation of platelets and the coagulation system, increasing the risk of death. The World Health Organization provided guidelines for the diagnosis and management of VITT, and authors summarized new clinically relevant information with recommendations for low resource environments.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Correction Radiology, Nuclear Medicine & Medical Imaging

Imaging and Hematologic Findings in Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 (AstraZeneca) Vaccination (Oct, 10.1148/radiol.2021219018, 2021)

Anmol Gangi et al.

RADIOLOGY (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Imaging and Hematologic Findings in Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 (AstraZeneca) Vaccination

Anmol Gangi et al.

Summary: This case series reports six patients who developed vaccine-induced thrombocytopenia and thrombosis after receiving the first dose of the ChAdOx1 nCoV-19 vaccine for COVID-19. The patients had high levels of antiplatelet factor 4 antibodies and experienced severe thrombosis. After receiving treatment, all patients recovered.

RADIOLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Pulmonary thrombosis in Covid-19: before, during and after hospital admission

Maria Vlachou et al.

Summary: The study found that pulmonary thrombosis is common in association with Covid-19, and the thrombotic risk in the pulmonary vasculature is present before and during hospital admission, and continues at least up to four weeks after discharge. The study also demonstrates the use of ultrasound-assisted catheter-directed thrombolysis (UACTD) for managing high and intermediate-high risk PE in Covid-19 patients.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)

Add to Collection

Article Medicine, General & Internal

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Marie Scully et al.

Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Nina H. Schultz et al.

Summary: This study reports five cases of venous thrombosis and thrombocytopenia occurring 7 to 10 days after receiving the ChAdOx1 nCoV-19 vaccine, suggesting a rare vaccine-induced immune thrombotic thrombocytopenia. The condition, which can lead to catastrophic outcomes such as cerebral venous sinus thrombosis, may be treated with intravenous immune globulin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Radiology, Nuclear Medicine & Medical Imaging

Imaging of Oxford/AstraZeneca® COVID-19 vaccine-induced immune thrombotic thrombocytopenia

Matthieu Garnier et al.

DIAGNOSTIC AND INTERVENTIONAL IMAGING (2021)

Add to Collection

Article Immunology

Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database

Mansour Tobaiqy et al.

Summary: The development of safe and effective vaccines against COVID-19 is crucial in the fight against the pandemic. Although some thrombotic adverse reactions were associated with the Oxford-AstraZeneca vaccine, the European Medicines Agency affirmed the vaccine's safety and effectiveness, with the benefits outweighing the risks. Conducting further analyses based on more detailed thrombotic adverse event reports may help evaluate causality with higher specificity.

VACCINES (2021)

Add to Collection

Editorial Material Hematology

Thrombocytopenia and splanchnic thrombosis after Ad26.COV2.S vaccination successfully treated with transjugular intrahepatic portosystemic shunting and thrombectomy

Roshni Dhoot et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study

Richard J. Perry et al.

Summary: The study documented cases of cerebral venous thrombosis after COVID-19 vaccination, finding that patients with VITT were younger, had more intracranial and extracranial thrombosis, and experienced worse outcomes compared to non-VITT patients. Treatments with non-heparin anticoagulants and intravenous immunoglobulin may improve outcomes in VITT-associated cerebral venous thrombosis.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal